Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $35.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price target lifted by Craig Hallum from $30.00 to $35.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also commented on ETON. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $39.33.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON opened at $22.32 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.57. The firm has a market cap of $608.89 million, a price-to-earnings ratio of -123.99 and a beta of 1.19. The business’s 50-day simple moving average is $16.72 and its 200-day simple moving average is $17.38. Eton Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.60%. The company had revenue of $21.28 million during the quarter, compared to the consensus estimate of $20.58 million. As a group, equities research analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ETON. Caitong International Asset Management Co. Ltd bought a new position in Eton Pharmaceuticals during the fourth quarter worth $50,000. Invesco Ltd. boosted its holdings in Eton Pharmaceuticals by 46.1% in the 4th quarter. Invesco Ltd. now owns 19,691 shares of the company’s stock valued at $333,000 after purchasing an additional 6,213 shares during the period. XTX Topco Ltd boosted its holdings in Eton Pharmaceuticals by 33.3% in the 4th quarter. XTX Topco Ltd now owns 32,527 shares of the company’s stock valued at $550,000 after purchasing an additional 8,128 shares during the period. Millennium Management LLC grew its position in Eton Pharmaceuticals by 400.1% in the 4th quarter. Millennium Management LLC now owns 79,331 shares of the company’s stock worth $1,341,000 after purchasing an additional 63,469 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in Eton Pharmaceuticals in the 4th quarter worth $178,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.